GlassScriptPhysician profile
Charde B Holt
NPI 1164075149
$1,091.47
in general payments reported to CMS, 2019-2025
13 companies · $707 in 2025
The $707 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $385 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.74 | 2024-2025 | Relistor |
| Curonix LLC | $262.75 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic, INC. | $86.92 | 2024-2025 | Inceptiv, Bio-Pump |
| Nalu Medical, INC. | $61.81 | 2024-2025 | Nalu Neurostimulation System |
| Lilly USA, LLC | $56.03 | 2024 | Mounjaro |
| Boston Scientific Corporation | $52.84 | 2025 | Intracept |
| Novo Nordisk INC | $31.67 | 2024 | Rybelsus, Ozempic |
| Nevro Corp. | $29.24 | 2024 | Senza |
| Abbvie INC. | $22.10 | 2025 | |
| Valinor Pharma, LLC | $20.73 | 2025 | Movantik |
| Tersera Therapeutics LLC | $20.48 | 2025 | Prialt |
| Saluda Medical Americas, INC. | $16.12 | 2025 | Evoke |
| Globus Medical, INC. | $16.04 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charde Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.